Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Lymphoid 1Endocrine 1

Conditions

Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thymoma 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma, Kaposi 1Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Pinealoma 1Penile Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

3-Iodobenzylguanidine 3olaparib 1lutetium Lu 177 dotatate 1entrectinib 1entinostat 1Pemetrexed 1Paclitaxel 1Dexamethasone 1Calcium Dobesilate 1Cabergoline 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × entinostat × Endocrine × Clear all
NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Columbia University

Phase 2 Terminated
5 enrolled 9 charts
EndocrineNET

Recurrence, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡